Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | LMB-100 |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | lung adenocarcinoma | no benefit | LMB-100 | Preclinical - Cell culture | Actionable | In a preclinical study, a CD274 (PD-L1) positive mouse lung adenocarcinoma cell line was not sensitive to treatment with LMB-100 in culture (PMID: 32611684). | 32611684 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32611684) | Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. | Full reference... |